The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations
This retrospective study was undertaken to investigate the impact of initial gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) versus chemotherapy on the risk of central nervous system (CNS) progression in advanced non-small cell lung cancer (NSCLC) with EGFR mutations.Patients with...
Sábháilte in:
Príomhchruthaitheoirí: | , , , , , , , , , |
---|---|
Formáid: | Artigo |
Teanga: | Béarla |
Foilsithe / Cruthaithe: |
2012
|
Rochtain ar líne: | https://doi.org/10.1158/1078-0432.ccr-12-0357 |
Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|